This series of 10 articles (four original articles, six reviews) is presented by international leaders in the field of NF-κB signaling in cancer and inflammation. While the reviews focus on the role of NF-κB signaling pathways in different types of solid tumors [1] [2] [3] [4] , B-cell lymphoma [5] and cancer stem cells [6] , the four included original publications [7-10] address these aspects in single-cell analysis, complex animal models, and state of the art expression analysis.
to HCC development. Thus, any NF-κB targeting approach can have beneficial but also disastrous effect. In the review the complexity of NF-κB signaling in primary liver and non-parenchymal cells is discussed, addressing this issue and leading to the conclusion that therapeutic interventions should particularly focus on immunotherapeutic approaches.
In addition to the discussion of HCC, the special issue includes a review of ovarian cancer [5] . For this cancer entity, many alterations in the NF-κB pathway are reported to lead to chemoresistance, cancer stem cell maintenance and self-renewal, metastasis and immune evasion. The aspect of cancer stem cells is extensively discussed in the manuscript by Kaltschmidt et al., focusing on this emerging field of research [6] . In ovarian cancer, NF-κB signaling can lead to an immune-evasive environment, accompanied by an enhanced tumor-promoting immune cell infiltration. In line with this central role of integrating the immune system in the development of solid cancer, the review of Geismann et al. [3] focus on the role of NF-κB controlled chemokine signaling in pancreatic cancer. These either autocrineor paracrine-acting chemokines can operate in a tumor-promoting or -inhibiting fashion, making a context-specific approach for the consideration of this signalling module in cancer therapy inevitable. In this context, for chemokines like CCL20 [11] and CX3CL1 [12] , an onco immuno crosstalk that leads to a NF-κB-dependent resistance against death receptor signaling is described. In addition to the Rel-subunit specific function in pancreatic cancer [1] , the two reviews on pancreatic cancer of this series confirm a central role of NF-κB in many aspects of this lethal tumor entity. The subunit-specific role in cancer is addressed in another review [5] for B cell lymphoma. In this disease, c-Rel is tightly regulated at multiple levels but alterations of these regulatory pathways as well as gene mutations and modifications in co-regulators like BCL11A and REL are frequently reported. Thus, in contrast to other tumors, c-Rel has a central role and is the only member of the Rel-family that can malignantly transform lymphoid cells in vitro.
In conclusion, this series of unique articles represents a collaborative, international effort to address all aspects of NF-κB signaling in cancer.
In the coming years, more work is needed to decipher the subunit-specific role of, but also the effects of, an altered NF-κB signaling pathway in the tumor cells with regard to the role of anti-stroma therapy, chemoresistance, and immunotherapy.
